Pharma penny stock under Rs 35 in green after acquiring 10,000 shares of its Singapore subsidiary
The stock gave multibagger returns of 467 per cent from its 52-week low of Rs 5.82 per share.
On Thursday, shares of Sudarshan Pharma Industries Ltd gained 1.66 per cent to Rs 33 per share from its previous closing of Rs 32.46 per share. The stock’s 52-week high is Rs 53.50 per share while its 52-week low is Rs 5.82 per share.
Sudarshan Pharma Industries Limited (SPIL) has finalised the acquisition of 10,000 ordinary shares of Sudarshan Pharma Industries Private Limited, Singapore, from Mr Amar Ashok Vyas for a total consideration of 10,000 Singapore Dollars (INR 635,500), as previously disclosed on November 29, 2024. This acquisition, conducted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, successfully establishes Sudarshan Singapore as a wholly-owned subsidiary of SPIL, marking a significant expansion of the company's international footprint.
On November 22, 2023, the shares of the company ex-traded sub-division /stock split of the company’s 1 (one) equity share having a face value of R 10 each fully paid-up, into 10 equity shares of the company having a face value of Re 1 each fully paid-up.
DSIJ’s ‘Micro Marvel' service recommends micro-cap stocks with the potential to grow multifold in long run. If this interests you, do download the service details here.
About the Company
Sudarshan Pharma Industries Limited (SPIL), established in 2008 and headquartered in Mumbai, is a prominent contract manufacturer of generic formulations. SPIL caters to a wide range of institutions and healthcare organisations operating across diverse segments, including speciality chemicals, intermediates, APIs, pharmaceutical and formulation generics, and bulk supply. Beyond its contract manufacturing services, SPIL has ventured into branded products through its Vimac Healthcare division. A significant portion of its product portfolio, consisting of 56 out of 96 items, is registered under the "R" trademark. Furthermore, SPIL collaborates with renowned Indian companies and institutional clients, offering contract manufacturing services for pharmaceutical formulations and medicines.
The company has a market cap of over Rs 700 crore and has delivered good profit growth of 37 per cent CAGR over the last 5 years. The stock gave multibagger returns of 467 per cent from its 52-week low of Rs 5.82 per share. Investors should keep an eye on this micro-cap stock.
Disclaimer: The article is for informational purposes only and not investment advice.